Department of Orthopedic Surgery, Warren Alpert Medical School of Brown University, 2 Dudley St, Providence, RI, 02905, USA.
Department of Orthopedic Surgery, Warren Alpert Medical School of Brown University, 2 Dudley St, Providence, RI, 02905, USA.
Spine J. 2020 Jan;20(1):69-77. doi: 10.1016/j.spinee.2019.08.014. Epub 2019 Sep 2.
Since 2016, 35 of 50 US states have passed opioid-limiting laws. The impact on postoperative opioid prescribing and secondary outcomes following anterior cervical discectomy and fusion (ACDF) remains unknown.
To evaluate the effect of opioid-limiting regulations on postoperative opioid prescriptions, emergency department (ED) visits, unplanned readmissions, and reoperations following elective ACDF.
STUDY DESIGN/SETTING: Retrospective review of prospectively-collected data.
Two hundred and eleven patients (101 pre-law, 110 post-law) undergoing primary elective 1-3 level ACDF during specified pre-law (December 1st, 2015-June 30th, 2016) and post-law (June 1st, 2017-December 31st, 2017) study periods were evaluated.
Demographic, medical, surgical, clinical, and pharmacological data was collected from all patients. Total morphine milligram equivalents (MMEs) filled was compared at 30-day postoperative intervals, before and after stratification by preoperative opioid-tolerance. Thirty- and 90-day ED visit, readmission, and reoperation rates were calculated. Independent predictors of increased 30-day and chronic (>90 day) opioid utilization were evaluated.
Demographic, medical, and surgical factors were similar pre-law versus post-law (all p>.05). Post-law, ACDF patients received fewer opioids in their first postoperative prescription (26.65 vs. 62.08 pills, p<.001; 202.23 vs. 549.18 MMEs, p<.001) and in their first 30 postoperative days (cumulative 30-day MMEs 444.14 vs. 877.87, p<.001). Furthermore, post-law reductions in cumulative 30-day MMEs were seen among both opioid-naïve (363.54 vs. 632.20 MMEs, p<.001) and opioid-tolerant (730.08 vs. 1,122.90 MMEs, p=.022) patient populations. Increased 30-day opioid utilization was associated with surgery in the pre-law period, preoperative opioid exposure, preoperative benzodiazepine exposure, and number of levels fused (all p<.05). Chronic (>90 day) opioid requirements were associated with preoperative opioid exposure (odds ratio 4.42, p<.001) but not with pre/post-law status (p>.05). Pre- and post-law patients were similar in terms of 30- or 90-day ED visits, unplanned readmissions, and reoperations (all p>.05).
Implementation of mandatory opioid prescribing limits effectively decreased 30-day postoperative opioid utilization following ACDF without a rebound increase in prescription refills, ED visits, unplanned hospital readmissions, or reoperations for pain.
自 2016 年以来,美国 50 个州中有 35 个州通过了限制阿片类药物的法律。但这对接受颈椎前路椎间盘切除融合术(ACDF)后的术后阿片类药物处方和次要结果的影响仍不清楚。
评估限制阿片类药物法规对接受择期 ACDF 后术后阿片类药物处方、急诊(ED)就诊、非计划再入院和再次手术的影响。
研究设计/设置:前瞻性收集数据的回顾性研究。
在指定的术前(2015 年 12 月 1 日-2016 年 6 月 30 日)和术后(2017 年 6 月 1 日-2017 年 12 月 31 日)研究期间,对 211 名接受原发性择期 1-3 级 ACDF 的患者(101 例术前,110 例术后)进行了评估。
从所有患者中收集人口统计学、医疗、手术、临床和药理学数据。比较了术前 30 天内和术后 30 天内的总吗啡毫克当量(MME)用量,并按术前阿片类药物耐受情况进行分层。计算了 30 天和 90 天 ED 就诊、再入院和再次手术的发生率。评估了增加 30 天和慢性(>90 天)阿片类药物使用的独立预测因素。
术前与术后的人口统计学、医疗和手术因素相似(均 p>.05)。术后,ACDF 患者术后第一个处方中的阿片类药物减少(26.65 片 vs. 62.08 片,p<.001;202.23 MMEs vs. 549.18 MMEs,p<.001),术后第一个 30 天的 MMEs 用量也减少(累积 30 天 MMEs 444.14 vs. 877.87,p<.001)。此外,在阿片类药物耐受和阿片类药物耐受的患者人群中,术后 30 天 MMEs 减少(363.54 vs. 632.20 MMEs,p<.001)和 632.20 MMEs(730.08 vs. 1,122.90 MMEs,p=.022)。增加的 30 天阿片类药物使用率与术前手术、术前阿片类药物暴露、术前苯二氮卓类药物暴露和融合的节段数相关(均 p<.05)。慢性(>90 天)阿片类药物需求与术前阿片类药物暴露相关(比值比 4.42,p<.001),但与术前/术后法律地位无关(p>.05)。术前和术后患者在 30 天或 90 天 ED 就诊、非计划再入院和再次手术方面相似(均 p>.05)。
强制性阿片类药物处方限制的实施有效减少了 ACDF 术后 30 天内的阿片类药物使用,但并未导致阿片类药物处方的后续增加、ED 就诊、非计划再入院或疼痛的再次手术。